3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Leukemia, Myeloid, Acute
14
Myelodysplastic Syndromes
7
Myeloproliferative Disorders
3
Myelodysplastic-Myeloproliferative Diseases
2
Leukemia, Myelomonocytic, Chronic
2
Triple Negative Breast Neoplasms
1
Thrombocythemia, Essential
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Leukemia, Biphenotypic, Acute
1
Hodgkin Disease
1
GATA2 Deficiency
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
BRCA1 Mutation
1
Anemia, Refractory, with Excess of Blasts
1
Allogeneic Stem Cell Transplantation
1
Interventions
lutetium Lu 177 dotatate
8
Specimen Handling
5
Magnetic Resonance Spectroscopy
5
pembrolizumab
3
olaparib
2
fludarabine
2
cabozantinib
2
X-Rays
2
Phantoms, Imaging
2
Cyclophosphamide
2
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
2
repotrectinib
1
peposertib
1
pazopanib
1
lenvatinib
1
fludarabine phosphate
1
entrectinib
1
belinostat
1
aldesleukin
1
Yttrium-90
1
Tomography, X-Ray Computed
1
Tomography, Emission-Computed, Single-Photon
1
Temozolomide
1
Single Photon Emission Computed Tomography Computed Tomography
1
Salts
1
Positron Emission Tomography Computed Tomography
1
PT-100 dipeptide
1
Octreotide
1
Nivolumab
1
Introns
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
decitabine and cedazuridine drug combination
×
30 days
×
Clear all
No trials found.